Eyal Lifschitz

Eyal Lifschitz is CEO, general partner, and co-founder of Peregrine Ventures.

Prior to founding Peregrine, Eyal co-founded and led the business development efforts of multiple medical technology companies, including PharmaSys (acquired by Elan Corp. NYSE:ELN), ECR (acquired by AVX Corp. NYSE:AVX), Visioncare Ophthalmic Technologies, and BioControl Ltd. From 2003-2007, Eyal also served as a director of Given Imaging (NASDAQ: GIVN).

Peregrine is an Israeli venture capital fund, with a focus on medical devices and an impressive record of founding, managing, and promoting Israeli hi-tech companies. Peregrine enjoys a wide network of contacts, and is supported by a investment committee and advisory board consisting of expert teams specializing in all applicable disciplines. The fund has invested in and initiated some of Israel’s leading medical companies, including Neovasc, B-Balloon, Valtech, Eximo, Memic, and Cordio.